Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (443)

Fever (98)

Cough (85)

Pneumonia (79)

Obesity (73)


Transmission

Seroprevalence
    displaying 211 - 220 records in total 443
    records per page




    High-Flow Nasal Cannula therapy: A Feasible Treatment in Vulnerable Older COVID-19 Patients on the Wards

    Authors: Job van Steenkiste; Michael C. van Herwerden; Dolf Weller; Christiaan J. van den Bout; Rikje Ruiter; Jan G. den Hollander; Rachida el Moussaoui; Gert T. Verhoeven; Charlotte van Noord; Marinus van den Dorpel

    doi:10.21203/rs.3.rs-34470/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: In the midst of the COVID-19 crisis, many frail elderly TRANS were admitted to our hospital with COVID-19. We sought a treatment for those who had severe respiratory failure HP respiratory failure MESHD but were not eligible for invasive mechanical ventilation, due to frailty, functional status, comorbidity or wish of the patient. We started with applying High-flow nasal cannula (HFNC) treatment on the wards.Methods: A retrospective cohort study amongst COVID-19 adult TRANS patients with respiratory failure HP respiratory failure MESHD defined as persisting hypoxemia HP hypoxemia MESHD despite maximum conventional oxygen administration requiring invasive mechanical ventilation at the Intensive Care Unit (ICU) but being treated with HFNC as they were non-eligible due to frailty or wish of the patient.Results: We included 32 patients between March 9 and May 1, 2020. The median age TRANS was 79.0 years (74.5-83.0) with a median of three comorbidities (3-4) and a median Clinical Frailty Score of 4 out of 9 (3-6). The median SPO2/FiO2 Ratio was 157.5 indicating moderate ARDS. Overall survival rate in the HFNC cohort was 25%. Age TRANS (80.5 (78.0-84.3) vs 69.5 (65.5-74.3) p=0.0040) and hypertension HP hypertension MESHD (92% vs 25%, p=0.0008) were associated with mortality.Conclusion: HFNC can be used as a last resort respiratory management strategy in vulnerable elderly TRANS COVID-19 patients in respiratory failure HP respiratory failure MESHD on the wards who failed on conventional high dose oxygen supply and are not eligible for invasive mechanical ventilation. 

    Factors Associated with the Poor Outcomes in Diabetic MESHD Patients with COVID-19

    Authors: Hadith Rastad; Hanieh-Sadat Ejtahed; Armita Mahdavi Ghorabi; Anis Safari; Ehsan Shahrestanaki; Mohammad Rezaei; Mohammad Mahdi Niksima; Akram Zakani; Seyede Hanieh Dehghan Manshadi; Fatemeh Ochi; Shabnam saedi; Zeinab Khodaparast; Neda Shafiabadi Hassani; Mehdi Azimzadeh; Mostafa Qorbani

    doi:10.21203/rs.3.rs-34111/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: Diabetic MESHD’s patients are supposed to experience higher rates of COVID-19 related poor outcomes. We aimed to determined factors predicting poor outcomes in hospitalized diabetic MESHD patients with COVID-19. Methods: This retrospective cohort study included all adult TRANS diabetic MESHD patients with radiological or laboratory confirmed COVID-19 who hospitalized between 20 February 2020 and 27 April 2020 in Alborz province, Iran. Data on demographic, medical history, and laboratory test at presentation were obtained from electronic medical records. Diagnosis of diabetes mellitus HP diabetes mellitus MESHD was self-reported. Comorbidities including cancer MESHD, rheumatism, immunodeficiency MESHD immunodeficiency HP, or chronic diseases of respiratory, liver, and blood SERO were classified as “other comorbidities” due to low frequency. The assessed poor outcomes were in-hospital mortality, need to ICU care, and receiving invasive mechanical ventilation. Self-reported. Multivariate logistic regression models were fitted to quantify the predictors of in-hospital mortality from COVID-19 in patients with DM MESHD. Results: Of 455 included patients, 98(21.5%) received ICU care, 65(14.3%) required invasive mechanical ventilation, and 79 (17.4%) dead. In the multivariate model, significant predictors of “death of COVID-19” were age TRANS  65 years or older (OR (95% CI): 2.0 (1.16-3.44), chronic kidney disease HP (CKD) (2.05 (1.16 -3.62), presence of “other comorbidities” (2.20 (1.04-4.63)), neutrophil count ≥ 8.0 × 10⁹/L )6.62 (3.73-11.7 ((, Hb level <12.5 g/dl (2.05 (1.13-3.72)(, and creatinine level ≥1.36 mg/dl (3.10 (1.38-6.98)). (All p –values < 0.05). Some of these factors were also associated with other assessed poor outcomes, e.g., need to ICU care or invasive mechanical ventilation.Conclusions: Diabetic patients with age TRANS 65 years or older, comorbidity CKD, “other comorbidities”, as well as neutrophil count ≥ 8.0 × 10⁹/L, Hb level <12.5 g/dl, and creatinine level ≥1.36 mg/dl, were more likely to dead after COVID-19. Presence of hypertension HP and cardiovascular disease were associated with none of the poor outcomes.

    What is the clinical course of patients hospitalised for COVID-19 treatment Ireland: a retrospective cohort study in Dublin’s North Inner City (the ‘Mater 100’)

    Authors: Brendan O’Kelly*; Colm Cronin*; Stephen Peter Connolly*; Walter Cullen; Gordana Avramovic; Tina McHugh; Eileen O’Connor; Aoife Cotter; Peter Doran; Tara McGinty; Dermot O’Callaghan; Sean Gaine; Gerard Sheehan; Eamonn Brazil; Brian Marsh; John S. Lambert

    doi:10.21203/rs.3.rs-34035/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: Since March 2020, Ireland has experienced an outbreak of coronavirus disease MESHD 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). To date, while several cohorts from China have been described, our understanding is limited, with no data describing the epidemiological and clinical characteristics of patients with COVID-19 in Ireland. To improve our understanding of the clinical characteristics of this emerging infection MESHD we carried out a retrospective review of patient data to examine the clinical characteristics of patients admitted for COVID-19 hospital treatment.Methods: Demographic, clinical and laboratory data on the first 100 adult TRANS patients admitted to Mater Misericordiae University Hospital (MMUH) for in-patient COVID-19 treatment after onset of the outbreak in March 2020 was extracted from clinical and administrative records. Missing data were excluded from the analysis.Results: Fifty-eight per cent were male TRANS, 63% were Irish nationals, 29% were GMS eligible, and median age TRANS was 45 years (interquartile range [IQR] =34-64 years). Patients had symptoms for a median of five days before diagnosis (IQR=2.5-7 days), most commonly cough HP (72%), fever HP fever MESHD (65%), dyspnoea MESHD (37%), fatigue HP fatigue MESHD (28%), myalgia HP myalgia MESHD (27%) and headache HP headache MESHD (24%). Of all cases, 54 had at least one pre-existing chronic illness (most commonly hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD or asthma HP asthma MESHD). At initial assessment, the most common abnormal findings were: C-reactive protein >7.0mg/L (74%), ferritin >247μg/L (women) or >275μg/L (men) (62%), D-dimer >0.5μg/dL (62%), chest imaging (59%), NEWS Score (modified) of ≥3 (55%) and heart rate >90/min (51%). Twenty-seven required supplemental oxygen, of which 17 were admitted to the intensive care unit - 14 requiring ventilation. Forty received antiviral treatment (most commonly hydroxychloroquine or lopinavir/ritonavir). Four died, 17 were admitted to intensive care, and 74 were discharged home, with nine days the median hospital stay (IQR=6-11).Conclusion: Our findings reinforce the emerging consensus of COVID-19 as an acute life-threatening disease and highlights, the importance of laboratory (ferritin, C-reactive protein, D-dimer) and radiological parameters, in addition to clinical parameters. Further cohort studies involving larger samples followed longitudinally are a priority.

    Effect of Early Oseltamivir on COVID-19-Suspected Outpatients without Hypoxia MESHD.

    Authors: Satoru Chiba

    doi:10.21203/rs.3.rs-34210/v1 Date: 2020-06-08 Source: ResearchSquare

    Background: Since December 2019, COVID-19 (corona virus disease 2019) outbreaks has occurred in China and many countries around the world. We evaluate the effectiveness of oseltamivir on COVID-19-suspected outpatients without hypoxia MESHD.Methods: We studied 13 COVID-19-suspected medical staffs and their cohabitation families without hypoxia MESHD, who came to our adult TRANS fever HP fever MESHD clinic from March to May 2020. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together. Results: Most of the infected MESHD patients were female TRANS (8 [62%]); less than half had diabetes MESHD (one [8%]) and hypertension HP hypertension MESHD (three [23%]). Median age TRANS was 45 years (IQR 26–53). Oseltamivir administration made the temperature fall HP within 24 hours in part (8 [62%]). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 hours, and patients administered late treatment (LT), initiated after this time point. Duration of fever HP fever MESHD was shorter in the ET group than in the LT group (33±24 versus 94±38 hours; p<0.01). The time from fever HP fever MESHD onset to treatment initiation correlated with duration of fever HP fever MESHD (r = 0.74; p<0.01) and the time from peak to decline (r = 0.55; p<0.05). Conclusions: Our findings suggest that early oseltamivir administration may lower the duration of fever HP fever MESHD in COVID-19-suspected outpatients without hypoxia MESHD when it is used in combination with antibacterial therapy.

    A Narrative Review on Evaluation of Hypercoagulability HP Hypercoagulability MESHD State in Severe COVID-19 Patients with Background Risk Factors

    Authors: Minoosh Moghimi; Kasra Khodadadi; Yousef Mortazavi

    id:10.20944/preprints202006.0062.v1 Date: 2020-06-07 Source: Preprints.org

    COVID-19 induces coagulopathy MESHD at the base of SIC MESHD ( sepsis HP sepsis MESHD-induced coagulopathy) and it is an important cause of death MESHD in the patients. Cytokine storm causes imbalance in coagulation MESHD and fibrinolytic system. A combination of hypercoagulability HP hypercoagulability MESHD state, decrease or inhibition of fibrinolytic and endothelialopathy causes thromboembolic MESHD events. Underlined disease with a high rate of mortality in COVID-19 like diabetes MESHD, hypertension HP hypertension MESHD and some conditions like aging and obesity HP obesity MESHD are the main disorders with hemostatic disturbance MESHD and increase of coagulopathy MESHD. Therefore, it seems that the combination of COVID-19 infection and these risk TRANS infection and these risk TRANS infection and these risk MESHD factors increase the risk of thromboembolic MESHD all together.

    Risk and protective factors of SARS-CoV-2 infection MESHD - Meta-regression of data from worldwide nations

    Authors: Hisato Takagi; Toshiki Kuno; Yujiro Yokoyama; Hiroki Ueyama; Takuya Matsushiro; Yosuke Hari; Tomo Ando

    doi:10.1101/2020.06.06.20124016 Date: 2020-06-07 Source: medRxiv

    Although it has been reported that coexistent chronic diseases MESHD are strongly associated with COVID-19 severity, investigations of predictors for SARS-CoV-2 infection MESHD itself have been seldom performed. To screen potential risk and protective factors for SARS-CoV-2 infection MESHD, meta-regression of data from worldwide nations were herein conducted. We extracted total confirmed COVID-19 cases in worldwide 180 nations (May 31, 2020), nation total population, population ages TRANS 0-14/65 and above, GDP/GNI per capita, PPP, life expectancy at birth, medical-doctor and nursing/midwifery-personnel density, hypertension HP hypertension MESHD/ obesity HP obesity MESHD/ diabetes MESHD prevalence SERO, annual PM2.5 concentrations, daily ultraviolet radiation, population using safely-managed drinking-water/sanitation services and hand-washing facility with soap/water, inbound tourism, and bachelor's MESHD or equivalent (ISCED 6). Restricted maximum-likelihood meta-regression in the random-effects model was performed using Comprehensive Meta-Analysis version 3. To adjust for other covariates, we conducted the hierarchical multivariate models. A slope (coefficient) of the meta-regression line for the COVID-19 prevalence SERO was significantly negative for population ages TRANS 0-14 (-0.0636; P = .0021) and positive for obesity HP obesity MESHD prevalence SERO (0.0411; P = .0099) and annual PM2.5 concentrations in urban areas (0.0158; P = .0454), which would indicate that the COVID-19 prevalence SERO decreases significantly as children TRANS increase and that the COVID-19 prevalence SERO increases significantly as the obese MESHD and PM2.5 increase. In conclusion, children TRANS (negatively) and obesity HP obesity MESHD/PM2.5 (positively) may be independently associated with SARS-CoV-2 infection MESHD.

    ACE2 levels are altered in comorbidities linked to severe outcome in COVID-19

    Authors: Valur Emilsson; Elias F Gudmundsson; Thor Aspelund; Brynjolfur G Jonsson; Alexander Gudjonsson; Lenore J Launer; John R Lamb; Valborg Gudmundsdottir; Lori L Jennings; Vilmundur Gudnason

    doi:10.1101/2020.06.04.20122044 Date: 2020-06-05 Source: medRxiv

    Aims: Severity of outcome in COVID-19 is disproportionately higher among the obese MESHD, males TRANS, smokers, those suffering from hypertension HP hypertension MESHD, kidney disease MESHD, coronary heart disease MESHD ( CHD MESHD) and/or type 2 diabetes MESHD (T2D). We examined if serum SERO levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2, were altered in these high-risk groups. Methods: Associations of serum SERO ACE2 levels to hypertension HP hypertension MESHD, T2D, obesity HP obesity MESHD, CHD MESHD, smokers and males TRANS in a single center population-based study of 5457 Icelanders from the Age TRANS, Gene/Environment Susceptibility Reykjavik Study ( AGES TRANS-RS) of the elderly TRANS (mean age TRANS 75+/-6 years). Results: Smokers, males TRANS, and individuals with T2D or obesity HP obesity MESHD have altered serum SERO levels of ACE2 that may influence productive infection of SARS-CoV-2 MESHD in these high-risk groups. Conclusion: ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as a circulating biomarker for severity of outcome in COVID-19.

    Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases

    Authors: Theodoros Giannouchos; Roberto Sussman; Jose Manuel Mier; Konstantinos Poulas; Konstantinos Farsalinos

    doi:10.1101/2020.06.04.20122481 Date: 2020-06-05 Source: medRxiv

    Background: There is insufficient information about risk factors for COVID-19 diagnosis and adverse outcomes from low and middle-income countries (LMICs). Objectives: We estimated the association between patients characteristics and COVID-19 diagnosis, hospitalization and adverse outcome in Mexico. Methods: This retrospective case series used a publicly available nation-level dataset released on May 31, 2020 by the Mexican Ministry of Health, with patients classified as suspected cases of viral respiratory disease MESHD. Patients with COVID-19 were laboratory-confirmed. Their profile was stratified by COVID-19 diagnosis or not. Differences among COVID-19 patients based on two separate clinical endpoints, hospitalization and adverse outcome, were examined. Multivariate logistic regressions examined the associations between patient characteristics and hospitalization and adverse outcome. Results: Overall, 236,439 patients were included, with 89,756 (38.0%) being diagnosed with COVID-19. COVID-19 patients were disproportionately older, males TRANS and with increased prevalence SERO of one or more comorbidities, particularly diabetes MESHD, obesity HP obesity MESHD, and hypertension HP hypertension MESHD. Age TRANS, male TRANS gender TRANS, diabetes MESHD, obesity HP obesity MESHD and having one or more comorbidities were independently associated with laboratory-confirmed COVID-19. Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. Of all COVID-19 patients, 34.8% were hospitalized and 13.0% experienced an adverse outcome. Male TRANS gender TRANS, older age TRANS, having one or more comorbidities, and chronic renal disease MESHD, diabetes MESHD, obesity HP obesity MESHD, COPD, immunosuppression and hypertension HP hypertension MESHD were associated with hospitalization and adverse outcome. Current smoking was not associated with adverse outcome. Conclusion: This largest ever case series of COVID-19 patients identified risk factors for COVID-19 diagnosis, hospitalization and adverse outcome. The findings could provide insight for the priorities the need to be set, especially by LMICs, to tackle the pandemic.

    A tertiary center experience of multiple myeloma HP multiple myeloma MESHD patients with COVID-19: lessons learned and the path forward

    Authors: Bo Wang; Oliver Van Oekelen; Tarek Mouhieddine; Diane Marie Del Valle; Joshua Richter; Hearn Jay Cho; Shambavi Richard; Ajai Chari; Sacha Gnjatic; Miriam Merad; Sundar Jagannath; Samir Parekh; Deepu Madduri

    doi:10.1101/2020.06.04.20122846 Date: 2020-06-05 Source: medRxiv

    Background: The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer MESHD patients and the organization of cancer MESHD care. Mount Sinai Hospital has a large and diverse multiple myeloma HP myeloma MESHD ( MM MESHD) population. Herein, we report the characteristics of COVID-19 infection MESHD and serological response in MM MESHD patients in a large tertiary care institution in New York. Methods: We performed a retrospective study on a cohort of 58 patients with a plasma SERO-cell disorder (54 MM MESHD, 4 smoldering MM MESHD) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti- SARS-CoV-2 antibody SERO testing, treatments initiated, and outcomes. Results: Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age TRANS was 67 years; 52% of patients were male TRANS and 63% were non-white. Hypertension HP Hypertension MESHD (64%), hyperlipidemia HP hyperlipidemia MESHD (62%), obesity HP obesity MESHD (37%), diabetes mellitus HP diabetes mellitus MESHD (28%), chronic kidney disease HP chronic kidney disease MESHD (24%) and lung disease MESHD (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age TRANS (>70 years), male TRANS sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia MESHD, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 SERO at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR. Conclusions: Drug exposure and MM MESHD disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia MESHD were associated with higher mortality. The majority of patients mounted an antibody SERO response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM MESHD patients who need early intervention to improve outcome in future outbreaks of COVID-19.

    Clinical Management and Mortality among COVID-19 Cases in Sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case data analysis

    Authors: Laura Skrip; Karim Derra; Mikaila Kaboré; Navideh Noori; Adama Gansané; Innocent Valéa; Halidou Tinto; Bicaba W. Brice; Mollie Van Gordon; Brittany Hagedorn; Hervé Hien; Benjamin Muir Althouse; Edward Wenger; André Lin Ouédraogo

    doi:10.1101/2020.06.04.20119784 Date: 2020-06-05 Source: medRxiv

    Background: Absolute numbers of COVID-19 cases and deaths MESHD reported to date in the sub-Saharan Africa (SSA) region have been significantly lower than those across the Americas, Asia, and Europe. As a result, there has been limited information about the demographic and clinical characteristics of deceased cases in the region, as well as the impacts of different case management strategies. Methods: Data from deceased cases reported across SSA through May 10, 2020 and from hospitalized cases in Burkina Faso through April 15, 2020 were analyzed. Demographic, epidemiological, and clinical information on deceased cases in SSA was derived through a line-list of publicly available information and, for cases in Burkina Faso, from aggregate records at the Center Hospitalier Universitaire de Tengandogo in Ouagadougou. A synthetic case population was derived probabilistically using distributions of age TRANS, sex, and underlying conditions from populations of West African countries to assess individual risk factors and treatment effect sizes. Logistic regression analysis was conducted to evaluate the adjusted odds of survival for patients receiving oxygen therapy or convalescent plasma SERO, based on therapeutic effectiveness observed for other respiratory illnesses. Results: Across SSA, deceased cases for which demographic data are available have been predominantly male TRANS (63/103, 61.2%) and over 50 years of age TRANS (59/75, 78.7%). In Burkina Faso, specifically, the majority of deceased cases either did not seek care at all or were hospitalized for a single day (59.4%, 19/32); hypertension HP hypertension MESHD and diabetes MESHD were often reported as underlying conditions. After adjustment for sex, age TRANS, and underlying conditions in the synthetic case population, the odds of mortality for cases not receiving oxygen therapy was significantly higher than those receiving oxygen, such as due to disruptions to standard care (OR: 2.07; 95% CI: 1.56-2.75). Cases receiving convalescent plasma SERO had 50% reduced odds of mortality than those who did not (95% CI: 0.24-0.93). Conclusion: Investment in sustainable production and maintenance of supplies for oxygen therapy, along with messaging around early and appropriate use for healthcare providers, caregivers, and patients could reduce COVID-19 deaths in SSA. Further investigation into convalescent plasma SERO is warranted, as data on its effectiveness specifically in treating COVID-19 becomes available. The success of supportive or curative clinical interventions will depend on earlier treatment seeking, such that community engagement and risk communication will be critical components of the response.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.